Clinical Trial Update: Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe [Phase 3]

View source ↗

Summary

Phase 3 trial update describing access to extended-release guanfacine HCl for European participants from SPD503-315/316; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• guanfacine HCl (extended-release) (guanfacine extended-release)

Snippet

Sponsor: Shire | Conditions: Attention Deficit Hyperactivity Disorder (ADHD) | Phase 3 | Status: COMPLETED | Results posted: 2017-05-18